Conexeu Sciences holder exercises 250K warrants
Conexeu Sciences Inc. ten percent owner Wright Michael G., through N3GU Investments LLC, exercised derivative securities to acquire 250,000 shares of Common Stock at $0.001 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Conexeu Sciences Inc. ten percent owner Wright Michael G., through N3GU Investments LLC, exercised derivative securities to acquire 250,000 shares of Common Stock at $0.001 per share. Following this transaction, N3GU Investments LLC indirectly holds 2,148,048 Common shares. The Performance Warrants were originally granted for services, totaling 900,000, of which 650,000 have vested; the remaining 250,000 will vest and be exercisable when the company submits a 510(k) application to the U.S. Food and Drug Administration.
Insider Trade Summary
250,000 shares exercised/converted
Exercise
2 txns
Insider
Wright Michael G.
Role
10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Performance Warrants | 250,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 250,000 | $0.001 | $250.00 |
Holdings After Transaction:
Performance Warrants — 250,000 contracts (Indirect, N3GU Investments LLC);
Common Stock — 2,148,048 shares (Indirect, N3GU Investments LLC)
Footnotes (2)
- F1. The reported securities are held directly by N3GU Investments LLC, a Wyoming limited liability company, over which the Reporting Person has sole voting and dispositive power.
- F2. 900,000 Performance Warrants were granted on June 5, 2025. The Performance Warrants were granted for services rendered to the Issuer and no price was paid for the Performance Warrants. 650,000 Performance Warrants have vested. The remaining 250,000 Performance Warrants will vest and be exercisable upon the Issuer submitting a 510(k) application to the United States Food and Drug Administration.
Key Figures
Common shares acquired: 250,000 shares
Exercise price: $0.001/share
Common shares held after: 2,148,048 shares
+5 more
8 metrics
Common shares acquired
250,000 shares
Common Stock acquired via derivative exercise on June 18, 2026
Exercise price
$0.001/share
Price per share for derivative exercise into Common Stock
Common shares held after
2,148,048 shares
Indirect Common Stock holdings following the reported transaction
Derivative shares exercised
250,000 warrants
Performance Warrants exercised into Common Stock
Performance Warrants granted
900,000 warrants
Total Performance Warrants granted on June 5, 2025 for services
Vested Performance Warrants
650,000 warrants
Portion of Performance Warrants that have vested
Unvested Performance Warrants
250,000 warrants
Will vest when a 510(k) FDA application is submitted
Warrant expiration
June 5, 2030
Expiration date for the Performance Warrants
Key Terms
Performance Warrants, voting and dispositive power, 510(k) application, United States Food and Drug Administration
4 terms
Performance Warrants financial
"900,000 Performance Warrants were granted on June 5, 2025."
voting and dispositive power financial
"over which the Reporting Person has sole voting and dispositive power."
510(k) application regulatory
"will vest and be exercisable upon the Issuer submitting a 510(k) application"
A 510(k) application is a regulatory submission to the U.S. Food and Drug Administration showing that a new medical device is substantially similar to an already approved device, so it can be cleared for marketing without the longest, most rigorous approval process. For investors, a cleared 510(k) means faster, lower-cost market access and lower regulatory risk compared with full approvals, which can speed revenue and reduce uncertainty — like getting permission to sell a new model because it’s close to an existing one.
United States Food and Drug Administration regulatory
"application to the United States Food and Drug Administration."
The United States Food and Drug Administration is the federal agency that reviews and authorizes foods, prescription and over‑the‑counter medicines, vaccines, medical devices and certain other health products for safety and effectiveness. Think of it as a national quality inspector whose approvals or rejections can determine whether a product can be sold, how quickly it reaches the market, and the size of its potential revenue—factors that directly affect a company’s risk and value for investors.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Conexeu Sciences (CNXU) report on this Form 4?
Conexeu Sciences reported that N3GU Investments LLC, associated with ten percent owner Wright Michael G., exercised derivative securities to acquire 250,000 shares of Common Stock at $0.001 per share, increasing its indirect holdings to 2,148,048 Common shares.
What are the key terms of the Conexeu Sciences (CNXU) Performance Warrants?
Conexeu Sciences granted 900,000 Performance Warrants on June 5, 2025, for services rendered, with no purchase price. Footnotes indicate 650,000 have vested and 250,000 will vest and be exercisable once the company submits a 510(k) application to the U.S. Food and Drug Administration.
What is the exercise price and expiration for the Conexeu Sciences (CNXU) Performance Warrants?
The Performance Warrants referenced carry a conversion or exercise price of $0.001 per underlying share of Common Stock and have an expiration date of June 5, 2030, according to the derivative transaction details in the filing.
What regulatory milestone affects vesting of Conexeu Sciences (CNXU) Performance Warrants?
The remaining 250,000 Performance Warrants will vest and become exercisable when Conexeu Sciences submits a 510(k) application to the United States Food and Drug Administration, tying part of the warrant vesting to this specific regulatory filing event.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates